← All trials
NCT05302531
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 4, 2022
- Primary completion
- Feb 29, 2024
- Completion date
- Apr 30, 2024
- First posted
- Mar 31, 2022
- Last posted
- Mar 31, 2022
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LorraineLead sponsor
- University of LorraineReponsible party - principal investigator
- University of LorraineOverall official - principal investigator
- FreseniusCollaborator
- Société Francophone Nutrition Clinique et MétabolismeCollaborator
- University of LorraineSponsor investigator
- University of LorraineOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.